Dai Ichi Life Insurance Company Ltd lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 180.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,971 shares of the company’s stock after acquiring an additional 12,201 shares during the quarter. Dai Ichi Life Insurance Company Ltd’s holdings in IDEXX Laboratories were worth $3,062,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of IDEXX Laboratories by 24.3% during the 1st quarter. Vanguard Group Inc. now owns 8,910,555 shares of the company’s stock valued at $1,377,660,000 after acquiring an additional 1,740,446 shares during the period. BlackRock Inc. grew its stake in shares of IDEXX Laboratories by 1,967.1% during the 1st quarter. BlackRock Inc. now owns 6,427,027 shares of the company’s stock valued at $993,680,000 after acquiring an additional 6,116,102 shares during the period. State Street Corp grew its stake in shares of IDEXX Laboratories by 38.6% during the 1st quarter. State Street Corp now owns 3,911,739 shares of the company’s stock valued at $604,793,000 after acquiring an additional 1,089,880 shares during the period. Renaissance Technologies LLC grew its stake in shares of IDEXX Laboratories by 59.1% during the 1st quarter. Renaissance Technologies LLC now owns 975,600 shares of the company’s stock valued at $150,838,000 after acquiring an additional 362,400 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of IDEXX Laboratories by 41.6% during the 1st quarter. Geode Capital Management LLC now owns 921,279 shares of the company’s stock valued at $142,250,000 after acquiring an additional 270,871 shares during the period. Institutional investors own 87.73% of the company’s stock.

In other IDEXX Laboratories news, Director Lawrence D. Kingsley acquired 2,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were bought at an average cost of $151.76 per share, with a total value of $303,520.00. Following the completion of the acquisition, the director now owns 3,344 shares in the company, valued at $507,485.44. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $154.91, for a total value of $2,788,380.00. Following the completion of the sale, the chief executive officer now directly owns 1,043,034 shares in the company, valued at $161,576,396.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 151,734 shares of company stock valued at $23,436,626. 2.77% of the stock is owned by company insiders.

A number of brokerages recently issued reports on IDXX. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 26th. Canaccord Genuity reiterated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, August 22nd. Bank of America Corporation upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a research note on Wednesday, August 23rd. Finally, BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $174.00.

IDEXX Laboratories, Inc. (IDXX) opened at 158.98 on Wednesday. IDEXX Laboratories, Inc. has a 1-year low of $102.45 and a 1-year high of $173.01. The firm has a 50-day moving average price of $156.10 and a 200 day moving average price of $158.64. The company has a market capitalization of $13.87 billion, a P/E ratio of 54.69 and a beta of 0.49.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. IDEXX Laboratories’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the business earned $0.74 earnings per share. On average, equities analysts predict that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/13/dai-ichi-life-insurance-company-ltd-buys-12201-shares-of-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.